{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:13:06Z","timestamp":1788455586451,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The relationship between diabetes mellitus (DM) and Alzheimer\u2019s disease (AD) is so strong that scientists called it \u201cbrain diabetes\u201d. According to several studies, the critical factor in this relationship is brain insulin resistance. Due to the rapid global spread of both diseases, overcoming this cross-talk has a significant impact on societies. Long non-coding RNAs (lncRNAs), on the other hand, have a substantial impact on complex diseases due to their ability to influence gene expression via a variety of mechanisms. Consequently, the regulation of lncRNA expression in chronic diseases permits the development of innovative therapeutic techniques. However, developing a new drug requires considerable time and money. Recently repurposing existing drugs has gained popularity due to the use of low-risk compounds, which may result in cost and time savings. in this study,\u00a0we identified drug repurposing candidates capable of controlling the expression of common lncRNAs in the cross-talk between DM and AD. We also utilized drugs that interfered with this cross-talk. To do this, high degree common lncRNAs were extracted from microRNA-lncRNA bipartite network. The drugs that interact with the specified lncRNAs were then collected from multiple data sources. These drugs, referred to as set D, were classified in to positive (D<jats:sup>+<\/jats:sup>) and negative (D<jats:sup>\u2212<\/jats:sup>) groups based on their effects on the expression of the interacting lncRNAs. A feature selection algorithm was used to select six important features for D. Using a random forest classifier, these features were capable of classifying D<jats:sup>+<\/jats:sup> and D<jats:sup>\u2212<\/jats:sup> with an accuracy of 82.5%. Finally, the same six features were extracted for the most recently Food and Drug Administration (FDA) approved drugs in order to identify those with the highest likelihood of belonging to D<jats:sup>+<\/jats:sup> or D<jats:sup>\u2212<\/jats:sup>. The most significant FDA-approved positive drugs, chromium nicotinate and tapentadol, were presented as repurposing candidates, while cefepime and dihydro-alpha-ergocryptine were recommended as significant adverse drugs. Moreover, two natural compounds, curcumin and quercetin, were recommended to prevent this cross-talk. According to the previous studies, less attention has been paid to the role of lncRNAs in this cross-talk. Our research not only did identify important lncRNAs, but it also suggested potential repurposed drugs to control them.<\/jats:p>","DOI":"10.1038\/s41598-022-22822-9","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T20:03:14Z","timestamp":1667246594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identification of repurposed drugs targeting significant long non-coding RNAs in the cross-talk between diabetes mellitus and Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Shokoofeh","family":"Ghiam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changiz","family":"Eslahchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koorosh","family":"Shahpasand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Habibi-Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Gharaghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"22822_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neubiorev.2016.03.005","volume":"64","author":"D Baglietto-Vargas","year":"2016","unstructured":"Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R. & LaFerla, F. M. Diabetes and Alzheimer\u2019s disease crosstalk. Neurosci. Biobehav. Rev. 64, 272\u2013287 (2016).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"22822_CR2","doi-asserted-by":"publisher","first-page":"113076","DOI":"10.1016\/j.expneurol.2019.113076","volume":"323","author":"EC McNay","year":"2020","unstructured":"McNay, E. C. & Pearson-Leary, J. GluT4: A central player in hippocampal memory and brain insulin resistance. Exp. Neuro.l 323, 113076 (2020).","journal-title":"Exp. Neuro.l"},{"issue":"5","key":"22822_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbadis.2016.08.018","volume":"1863","author":"R Kandimalla","year":"2017","unstructured":"Kandimalla, R., Thirumala, V. & Reddy, P. H. Is Alzheimer\u2019s disease a Type 3 diabetes? A critical appraisal. Biochim. Biophys. Acta 1863(5), 1078\u20131089 (2017).","journal-title":"Biochim. Biophys. Acta"},{"issue":"2 Suppl 1","key":"22822_CR4","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/j.dsx.2016.01.021","volume":"10","author":"K Mittal","year":"2016","unstructured":"Mittal, K. & Katare, D. P. Shared links between type 2 diabetes mellitus and Alzheimer\u2019s disease: A review. Diabetes Metab. Syndr. 10(2 Suppl 1), S144-149 (2016).","journal-title":"Diabetes Metab. Syndr."},{"issue":"1","key":"22822_CR5","doi-asserted-by":"publisher","first-page":"25589","DOI":"10.1038\/srep25589","volume":"6","author":"K Mittal","year":"2016","unstructured":"Mittal, K., Mani, R. J. & Katare, D. P. Type 3 diabetes: Cross talk between differentially regulated proteins of type 2 diabetes mellitus and Alzheimer\u2019s disease. Sci. Rep. 6(1), 25589 (2016).","journal-title":"Sci. Rep."},{"issue":"2","key":"22822_CR6","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3233\/JAD-170440","volume":"60","author":"R Karki","year":"2017","unstructured":"Karki, R., Kodamullil, A. T. & Hofmann-Apitius, M. Comorbidity analysis between Alzheimer\u2019s disease and type 2 diabetes mellitus (T2DM) based on shared pathways and the role of T2DM drugs. J. Alzheimer\u2019s Dis. JAD 60(2), 721\u2013731 (2017).","journal-title":"J. Alzheimer's Dis. JAD"},{"issue":"1","key":"22822_CR7","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1038\/s41598-020-60682-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu, Z. et al. Shared causal paths underlying Alzheimer\u2019s dementia and type 2 diabetes. Sci. Rep. 10(1), 4107 (2020).","journal-title":"Sci. Rep."},{"key":"22822_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4939-7471-9_6","volume":"1706","author":"JK DiStefano","year":"2018","unstructured":"DiStefano, J. K. The emerging role of long noncoding RNAs in human disease. Methods Mol. Biol. (Clifton, NJ) 1706, 91\u2013110 (2018).","journal-title":"Methods Mol. Biol. (Clifton, NJ)"},{"issue":"17","key":"22822_CR9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/1873-3468.13182","volume":"592","author":"E Lekka","year":"2018","unstructured":"Lekka, E. & Hall, J. Noncoding RNAs in disease. FEBS Lett 592(17), 2884\u20132900 (2018).","journal-title":"FEBS Lett"},{"issue":"5","key":"22822_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.gpb.2012.07.005","volume":"10","author":"Y Li","year":"2012","unstructured":"Li, Y. & Kowdley, K. V. MicroRNAs in common human diseases. Genomics Proteomics Bioinform. 10(5), 246\u2013253 (2012).","journal-title":"Genomics Proteomics Bioinform."},{"issue":"1","key":"22822_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000356447","volume":"1","author":"SK Natarajan","year":"2013","unstructured":"Natarajan, S. K., Smith, M. A., Wehrkamp, C. J., Mohr, A. M. & Mott, J. L. MicroRNA function in human diseases. Med. Epigenet. 1(1), 106\u2013115 (2013).","journal-title":"Med. Epigenet."},{"issue":"2","key":"22822_CR12","doi-asserted-by":"publisher","first-page":"e1463","DOI":"10.1002\/wrna.1463","volume":"9","author":"ML Idda","year":"2018","unstructured":"Idda, M. L., Munk, R., Abdelmohsen, K. & Gorospe, M. Noncoding RNAs in Alzheimer\u2019s disease. Wiley Interdiscip. Rev. RNA 9(2), e1463 (2018).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"issue":"41","key":"22822_CR13","doi-asserted-by":"publisher","first-page":"71325","DOI":"10.18632\/oncotarget.19921","volume":"8","author":"X He","year":"2017","unstructured":"He, X. et al. LncRNAs: Key players and novel insights into diabetes mellitus. Oncotarget 8(41), 71325\u201371341 (2017).","journal-title":"Oncotarget"},{"key":"22822_CR14","doi-asserted-by":"publisher","first-page":"654978","DOI":"10.3389\/fnagi.2021.654978","volume":"13","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. The role of non-coding RNAs in Alzheimer\u2019s disease: from regulated mechanism to therapeutic targets and diagnostic biomarkers. Front. Aging Neurosci. 13, 654978 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"22822_CR15","doi-asserted-by":"publisher","first-page":"955461","DOI":"10.3389\/fnagi.2022.955461","volume":"14","author":"S Ghiam","year":"2022","unstructured":"Ghiam, S., Eslahchi, C., Shahpasand, K., Habibi-Rezaei, M. & Gharaghani, S. Exploring the role of non-coding RNAs as potential candidate biomarkers in the cross-talk between diabetes mellitus and Alzheimer\u2019s disease. Front. Aging Neurosci. 14, 955461 (2022).","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"22822_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","volume":"16","author":"M Matsui","year":"2017","unstructured":"Matsui, M. & Corey, D. R. Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 16(3), 167\u2013179 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"22822_CR17","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1002\/jcb.26036","volume":"118","author":"S Shakil","year":"2017","unstructured":"Shakil, S. Molecular interaction of anti-diabetic drugs with acetylcholinesterase and sodium glucose co-transporter 2. J. Cell. Biochem. 118(11), 3855\u20133865 (2017).","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"22822_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.nlm.2011.08.005","volume":"96","author":"EC McNay","year":"2011","unstructured":"McNay, E. C. & Recknagel, A. K. Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Mem. 96(3), 432\u2013442 (2011).","journal-title":"Neurobiol. Learn. Mem."},{"issue":"D1","key":"22822_CR19","first-page":"D148","volume":"48","author":"H-Y Huang","year":"2019","unstructured":"Huang, H.-Y. et al. MiRTarBase 2020: Updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 48(D1), D148\u2013D154 (2019).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"22822_CR20","first-page":"D101","volume":"48","author":"D Karagkouni","year":"2019","unstructured":"Karagkouni, D. et al. DIANA-LncBase v3: Indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res. 48(D1), D101\u2013D110 (2019).","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"22822_CR21","doi-asserted-by":"publisher","first-page":"D202","DOI":"10.1093\/nar\/gkq1056","volume":"39","author":"JH Yang","year":"2011","unstructured":"Yang, J. H. et al. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 39(Database issue), D202-209 (2011).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"22822_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1080\/15476286.2019.1649584","volume":"16","author":"W Jiang","year":"2019","unstructured":"Jiang, W. et al. D-lnc: A comprehensive database and analytical platform to dissect the modification of drugs on lncRNA expression. RNA Biol. 16(11), 1586\u20131591 (2019).","journal-title":"RNA Biol."},{"issue":"1","key":"22822_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-020-00849-7","volume":"13","author":"L Li","year":"2020","unstructured":"Li, L. et al. NoncoRNA: A database of experimentally supported non-coding RNAs and drug targets in cancer. J. Hematol. Oncol. 13(1), 15 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"22822_CR24","doi-asserted-by":"publisher","unstructured":"DrugBank 5.0: a major update to the DrugBank database for 2018. https:\/\/doi.org\/10.1093\/nar\/gkx1037.","DOI":"10.1093\/nar\/gkx1037"},{"key":"22822_CR25","unstructured":"Openbabel. http:\/\/openbabel.org\/."},{"key":"22822_CR26","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jcc.21707","volume":"32","author":"CW Yap","year":"2011","unstructured":"Yap, C. W. PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints. J. Comput. Chem. 32, 1466\u20131474 (2011).","journal-title":"J. Comput. Chem."},{"key":"22822_CR27","doi-asserted-by":"crossref","unstructured":"Bounsiar, A. & Madden, M. G. Kernels for One-class support vector machines. In: 2014 International Conference on Information Science & Applications (ICISA): 6\u20139 May 2014. 1\u20134. (2014).","DOI":"10.1109\/ICISA.2014.6847419"},{"issue":"3","key":"22822_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00702-010-0436-1","volume":"118","author":"HM Schipper","year":"2011","unstructured":"Schipper, H. M. Heme oxygenase-1 in Alzheimer disease: A tribute to Moussa Youdim. J. Neural Transm. 118(3), 381\u2013387 (2011).","journal-title":"J. Neural Transm."},{"key":"22822_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3389\/fnins.2016.00459","volume":"10","author":"A Vall\u00e9e","year":"2016","unstructured":"Vall\u00e9e, A. & Lecarpentier, Y. Alzheimer disease: Crosstalk between the canonical Wnt\/Beta-catenin pathway and PPARs alpha and gamma. Front. Neurosci. 10, 459 (2016).","journal-title":"Front. Neurosci."},{"key":"22822_CR30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2337\/diab.46.7.1230","volume":"46","author":"KS Park","year":"1997","unstructured":"Park, K. S. et al. PPAR-gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 46, 1230\u20131234 (1997).","journal-title":"Diabetes"},{"key":"22822_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fnins.2019.00629","volume":"13","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj, S. et al. Altered insulin signaling in Alzheimer\u2019s disease brain\u2014special emphasis on PI3K-Akt pathway. Front. Neurosci. 13, 629 (2019).","journal-title":"Front. Neurosci."},{"key":"22822_CR32","doi-asserted-by":"publisher","first-page":"626636","DOI":"10.3389\/fnins.2021.626636","volume":"15","author":"N Kyrtata","year":"2021","unstructured":"Kyrtata, N., Emsley, H., Sparasci, O., Parkes, L. & Dickie, B. A systematic review of glucose transport alterations in Alzheimer\u2019s disease. Front. Neurosci. 15, 626636 (2021).","journal-title":"Front. Neurosci."},{"key":"22822_CR33","doi-asserted-by":"publisher","first-page":"13576","DOI":"10.1073\/pnas.0902714106","volume":"106","author":"C Massaad","year":"2009","unstructured":"Massaad, C., Washington, T., Pautler, R. & Klann, E. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. U.S.A. 106, 13576\u201313581 (2009).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"22822_CR34","doi-asserted-by":"publisher","first-page":"112681","DOI":"10.1016\/j.biopha.2022.112681","volume":"148","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. MicroRNAs in Alzheimer\u2019s disease: Potential diagnostic markers and therapeutic targets. Biomed. Pharmacother. 148, 112681 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"22822_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-018-0132-z","volume":"12","author":"S Chandrakumar","year":"2018","unstructured":"Chandrakumar, S., Prabu, P., Mohan, V. & Balasubramanyam, M. Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes. Hum. Genomics 12, 1\u20139 (2018).","journal-title":"Hum. Genomics"},{"key":"22822_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fncel.2020.00028","volume":"14","author":"Z Huang","year":"2020","unstructured":"Huang, Z., Zhao, J., Wang, W., Zhou, J. & Zhang, J. Depletion of LncRNA NEAT1 rescues mitochondrial dysfunction through NEDD4L-dependent PINK1 degradation in animal models of Alzheimer\u2019s disease. Front. Cell. Neurosci. 14, 28 (2020).","journal-title":"Front. Cell. Neurosci."},{"key":"22822_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/cbin.11263","volume":"44","author":"D Yue","year":"2019","unstructured":"Yue, D. et al. Silencing of long noncoding RNA XIST attenuated Alzheimer\u2019s disease-related BACE1 alteration through miR-124. Cell Biol. Int. 44, 630\u2013636 (2019).","journal-title":"Cell Biol. Int."},{"issue":"7","key":"22822_CR38","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.1002\/jcp.27746","volume":"234","author":"JL Yu","year":"2019","unstructured":"Yu, J. L., Li, C., Che, L. H., Zhao, Y. H. & Guo, Y. B. Downregulation of long noncoding RNA H19 rescues hippocampal neurons from apoptosis and oxidative stress by inhibiting IGF2 methylation in mice with streptozotocin-induced diabetes mellitus. J. Cell. Physiol. 234(7), 10655\u201310670 (2019).","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"22822_CR39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/1567205016666190725130134","volume":"16","author":"P Ma","year":"2019","unstructured":"Ma, P. et al. Long non-coding RNA MALAT1 inhibits neuron apoptosis and neuroinflammation while stimulates neurite outgrowth and its correlation with MiR-125b mediates PTGS2, CDK5 and FOXQ1 in Alzheimer\u2019s disease. Curr. Alzheimer Res. 16(7), 596\u2013612 (2019).","journal-title":"Curr. Alzheimer Res."},{"issue":"4","key":"22822_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.7150\/ijms.30097","volume":"16","author":"LE Abdulle","year":"2019","unstructured":"Abdulle, L. E. et al. MALAT1 as a diagnostic and therapeutic target in diabetes-related complications: A promising long-noncoding RNA. Int. J. Med. Sci. 16(4), 548\u2013555 (2019).","journal-title":"Int. J. Med. Sci."},{"key":"22822_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fbioe.2020.00553","volume":"8","author":"G Geng","year":"2020","unstructured":"Geng, G., Zhang, Z. & Cheng, L. Identification of a multi-long noncoding RNA signature for the diagnosis of type 1 diabetes mellitus. Front. Bioeng. Biotechnol. 8, 553 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"22822_CR42","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.2147\/DMSO.S333431","volume":"14","author":"Y Xia","year":"2021","unstructured":"Xia, Y., Zhang, Y. & Wang, H. Upregulated lncRNA HCG18 in patients with non-alcoholic fatty liver disease and its regulatory effect on insulin resistance. Diabetes Metab. Syndr. Obes. 14, 4747\u20134756 (2021).","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"7","key":"22822_CR43","doi-asserted-by":"publisher","first-page":"e0126566","DOI":"10.1371\/journal.pone.0126566","volume":"10","author":"T Yan-Fang","year":"2015","unstructured":"Yan-Fang, T. et al. Molecular mechanism of the cell death induced by the histone deacetylase pan inhibitor LBH589 (panobinostat) in wilms tumor cells. PLoS ONE 10(7), e0126566 (2015).","journal-title":"PLoS ONE"},{"issue":"7","key":"22822_CR44","doi-asserted-by":"publisher","first-page":"11200","DOI":"10.1002\/jcp.27770","volume":"234","author":"S Huang","year":"2019","unstructured":"Huang, S. et al. Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt\/mTOR signaling pathway. J. Cell. Physiol. 234(7), 11200\u201311207 (2019).","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"22822_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/cbin.11263","volume":"44","author":"D Yue","year":"2020","unstructured":"Yue, D. et al. Silencing of long noncoding RNA XIST attenuated Alzheimer\u2019s disease-related BACE1 alteration through miR-124. Cell Biol. Int. 44(2), 630\u2013636 (2020).","journal-title":"Cell Biol. Int."},{"issue":"1","key":"22822_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/15384101.2020.1863681","volume":"20","author":"YY Zhang","year":"2021","unstructured":"Zhang, Y. Y. et al. Silenced lncRNA H19 and up-regulated microRNA-129 accelerates viability and restrains apoptosis of PC12 cells induced by A\u03b2(25\u201335) in a cellular model of Alzheimer\u2019s disease. Cell Cycle (Georgetown, Tex) 20(1), 112\u2013125 (2021).","journal-title":"Cell Cycle (Georgetown, Tex)"},{"key":"22822_CR47","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.yexmp.2020.104545","volume":"117","author":"L Li","year":"2020","unstructured":"Li, L., Xu, Y., Zhao, M. & Gao, Z. Neuro-protective roles of long non-coding RNA MALAT1 in Alzheimer\u2019s disease with the involvement of the microRNA-30b\/CNR1 network and the following PI3K\/AKT activation. Exp. Mol. Pathol. 117, 104545 (2020).","journal-title":"Exp. Mol. Pathol."},{"issue":"3","key":"22822_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.2337\/dbi16-0063","volume":"66","author":"F Mauvais-Jarvis","year":"2017","unstructured":"Mauvais-Jarvis, F. Is estradiol a biomarker of type 2 diabetes risk in postmenopausal women?. Diabetes 66(3), 568\u2013570 (2017).","journal-title":"Diabetes"},{"issue":"3","key":"22822_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-2011-110341","volume":"26","author":"W Wharton","year":"2011","unstructured":"Wharton, W. et al. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer\u2019s disease: Results of a randomized controlled trial. J. Alzheimer\u2019s Dis. JAD 26(3), 495\u2013505 (2011).","journal-title":"J. Alzheimer's Dis. JAD"},{"issue":"3","key":"22822_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1179\/147683010X12611460764084","volume":"13","author":"R Krikorian","year":"2010","unstructured":"Krikorian, R., Eliassen, J. C., Boespflug, E. L., Nash, T. A. & Shidler, M. D. Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr. Neurosci. 13(3), 116\u2013122 (2010).","journal-title":"Nutr. Neurosci."},{"issue":"2","key":"22822_CR51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4081\/gc.2017.6900","volume":"3","author":"E Nunziata","year":"2017","unstructured":"Nunziata, E., De Siati, F. & Palleschi, L. Effectiveness and tolerability of tapentadol in very elderly patients with assessment of cognitive-behavioral aspects. Geriatr. Care 3(2), 973\u2013982 (2017).","journal-title":"Geriatr. Care"},{"issue":"1","key":"22822_CR52","first-page":"41","volume":"16","author":"AGMJM Bueno","year":"2018","unstructured":"Bueno, A. G. M. J. M. & German, C. I. Tapentadol, a new horizon in the treatment of diabetic peripheral painful neuropathy. Acta Med. 16(1), 41\u201346 (2018).","journal-title":"Acta Med."},{"issue":"8","key":"22822_CR53","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/jnnp.2003.025858","volume":"75","author":"MC Morris","year":"2004","unstructured":"Morris, M. C. et al. Dietary niacin and the risk of incident Alzheimer\u2019s disease and of cognitive decline. J. Neurol. Neurosurg. Psychiatry 75(8), 1093\u20131099 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"22822_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mce.2015.01.029","volume":"404","author":"L Chen","year":"2015","unstructured":"Chen, L. et al. Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. Mol. Cell. Endocrinol. 404, 56\u201366 (2015).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"22822_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6823-10-3","volume":"10","author":"P Weeke","year":"2010","unstructured":"Weeke, P. et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus\u2014an analysis from the SCOUT lead-in period. BMC Endocr. Disord. 10(1), 3 (2010).","journal-title":"BMC Endocr. Disord."},{"issue":"6","key":"22822_CR56","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/brainsci10060386","volume":"10","author":"O S\u00e1iz-Vazquez","year":"2020","unstructured":"S\u00e1iz-Vazquez, O., Puente-Mart\u00ednez, A., Ubillos-Landa, S., Pacheco-Bonrostro, J. & Santab\u00e1rbara, J. Cholesterol and Alzheimer\u2019s disease risk: A meta-meta-analysis. Brain Sci. 10(6), 386 (2020).","journal-title":"Brain Sci."},{"issue":"1","key":"22822_CR57","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1038\/s41467-020-18114-3","volume":"11","author":"G Egervari","year":"2020","unstructured":"Egervari, G. et al. Chromatin accessibility mapping of the striatum identifies tyrosine kinase FYN as a therapeutic target for heroin use disorder. Nat. Commun. 11(1), 4634 (2020).","journal-title":"Nat. Commun."},{"issue":"17","key":"22822_CR58","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1097\/MD.0000000000000809","volume":"94","author":"HI Shih","year":"2015","unstructured":"Shih, H. I. et al. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: A population-based case-control study. Medicine 94(17), e809 (2015).","journal-title":"Medicine"},{"issue":"11","key":"22822_CR59","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40263-016-0374-z","volume":"30","author":"RC Chou","year":"2016","unstructured":"Chou, R. C., Kane, M., Ghimire, S., Gautam, S. & Gui, J. Treatment for rheumatoid arthritis and risk of Alzheimer\u2019s disease: A nested case-control analysis. CNS Drugs 30(11), 1111\u20131120 (2016).","journal-title":"CNS Drugs"},{"issue":"6","key":"22822_CR60","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.4158\/ACCR-2018-0067","volume":"4","author":"GA Stamatiades","year":"2018","unstructured":"Stamatiades, G. A., Echouffo-Tcheugui, J. B. & Garber, J. R. Sulfasalazine-induced hypoglycemia in a patient with type 2 diabetes and end-stage renal disease. AACE Clin. Case Rep. 4(6), e493\u2013e496 (2018).","journal-title":"AACE Clin. Case Rep."},{"issue":"3","key":"22822_CR61","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1503\/cmaj.050478","volume":"173","author":"S Singh","year":"2005","unstructured":"Singh, S. & Wooltorton, E. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ Can. Med. Assoc. J. 173(3), 252 (2005).","journal-title":"CMAJ Can. Med. Assoc. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22822-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22822-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22822-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T20:07:57Z","timestamp":1667246877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22822-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22822"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22822-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18332"}}